Related Experiment Video

Updated: Nov 18, 2025

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae
06:04

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae

Published on: February 24, 2023

2.7K

Mycoplasma pneumoniae: a pathogen with unsolved therapeutic problems

Susanna Esposito1, Alberto Argentiero1, Andrea Gramegna2,3

  • 1Pediatric Clinic, Pietro Barilla Children's Hospital, University of Parma, Parma, Italy.

Expert Opinion on Pharmacotherapy
|February 5, 2021
PubMed
Abstract

Insights

Effective treatment for macrolide-resistant Mycoplasma pneumoniae infections in children remains unclear. Further research is needed to establish optimal therapies and clarify the role of corticosteroids in severe cases.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Pharmacology

Background:

  • The optimal diagnosis and treatment for Mycoplasma pneumoniae infections are not well-established.
  • Macrolide-resistant (ML) M. pneumoniae infections in children present therapeutic challenges.
  • The epidemiology and role of M. pneumoniae in extra-respiratory manifestations require further investigation.

Purpose of the Study:

  • To review pharmacological options for treating macrolide-resistant M. pneumoniae infections in children.
  • To discuss the clinical relevance of macrolide resistance in M. pneumoniae infections.
  • To evaluate the role of corticosteroids in severe M. pneumoniae cases.

Main Methods:

  • Narrative review of existing literature.
  • Discussion of pharmacological treatment strategies.
  • Analysis of diagnostic and therapeutic challenges.

Main Results:

  • The clinical significance of ML resistance in M. pneumoniae is not precisely defined.
  • The necessity of antibiotic use in all cases is debated.
  • The benefit of corticosteroids in severe cases, including those with ML-resistant strains, is uncertain.

Conclusions:

  • Improved M. pneumoniae identification is crucial to minimize antibiotic overuse, particularly with ML-resistant strains.
  • Future studies should prioritize evaluating the benefits of corticosteroids in severe community-acquired pneumonia (CAP) and extra-respiratory M. pneumoniae diseases.
Keywords:
Atypical bacteriaMcoplasma pneumoniaefluoroquinolonemacrolidemacrolide-resistance

More Related Videos

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.3K
A Non-invasive and Technically Non-intensive Method for Induction and Phenotyping of Experimental Bacterial Pneumonia in Mice07:43

A Non-invasive and Technically Non-intensive Method for Induction and Phenotyping of Experimental Bacterial Pneumonia in Mice

Published on: September 28, 2016

9.3K

Related Concept Videos

Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
1.8K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
580
Bacterial Phylum Tenericutes01:24

Bacterial Phylum Tenericutes

The phylum Tenericutes, which includes the single class Mollicutes, comprises bacteria that lack cell walls. The term "Mollicutes" derives from the Latin word mollis, meaning "soft." These organisms are among the smallest known and are commonly referred to as mycoplasmas due to the prominence of the genus Mycoplasma, which includes well-known human pathogens. Despite their inability to stain gram-positively (a result of their lack of cell walls), mycoplasmas are phylogenetically related to the...
244
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
590
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
497
Defense Against Bacterial Pathogens01:31

Defense Against Bacterial Pathogens

The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
1.8K